Oral L-carnitine: metabolite formation and hemodialysis
MA Bain, R Faull, RW Milne… - Current drug …, 2006 - ingentaconnect.com
MA Bain, R Faull, RW Milne, AM Evans
Current drug metabolism, 2006•ingentaconnect.comL-Carnitine has important roles in intermediary metabolism and patients with end-stage
renal disease who are undergoing hemodialysis may develop a secondary L-carnitine
deficiency. The extent of accumulation of the metabolites trimethylamine and trimethylamine-
N-oxide when L-carnitine is administered orally has not been investigated previously in this
population. Oral L-carnitine at a dose of 1 g daily was administered for twelve days to six
patients with end-stage renal disease undergoing hemodialysis thrice weekly. Pre-dialysis …
renal disease who are undergoing hemodialysis may develop a secondary L-carnitine
deficiency. The extent of accumulation of the metabolites trimethylamine and trimethylamine-
N-oxide when L-carnitine is administered orally has not been investigated previously in this
population. Oral L-carnitine at a dose of 1 g daily was administered for twelve days to six
patients with end-stage renal disease undergoing hemodialysis thrice weekly. Pre-dialysis …
L-Carnitine has important roles in intermediary metabolism and patients with end-stage renal disease who are undergoing hemodialysis may develop a secondary L-carnitine deficiency. The extent of accumulation of the metabolites trimethylamine and trimethylamine-N-oxide when L-carnitine is administered orally has not been investigated previously in this population. Oral L-carnitine at a dose of 1 g daily was administered for twelve days to six patients with end-stage renal disease undergoing hemodialysis thrice weekly. Pre-dialysis plasma concentrations of L-carnitine (mean ± SD) increased significantly (P
ingentaconnect.com